[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 20 of about 20
1. Takada T, Amano H, Yasuda H, Nimura Y, Matsushiro T, Kato H, Nagakawa T, Nakayama T, Study Group of Surgical Adjuvant Therapy for Carcinomas of the Pancreas and Biliary Tract: Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma. Cancer; 2002 Oct 15;95(8):1685-95
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Is postoperative adjuvant chemotherapy useful for gallbladder carcinoma? A phase III multicenter prospective randomized controlled trial in patients with resected pancreaticobiliary carcinoma.
  • BACKGROUND: To the authors' knowledge, the significance of postoperative adjuvant chemotherapy in pancreaticobiliary carcinoma has not yet been clarified.
  • A randomized controlled study evaluated the effect of postoperative adjuvant therapy with mitomycin C (MMC) and 5-fluorouracil (5-FU) (MF arm) versus surgery alone (control arm) on survival and disease-free survival (DFS) for each specific disease comprising resected pancreaticobiliary carcinoma (pancreatic, gallbladder, bile duct, or ampulla of Vater carcinoma) separately.
  • METHODS: Between April 1986 and June 1992, a total of 508 patients with resected pancreatic (n = 173), bile duct (n = 139), gallbladder (n = 140), or ampulla of Vater (n = 56) carcinomas were allocated randomly to either the MF group or the control group.
  • ]) at the time of surgery and 5-FU (310 mg/m(2) i.v.) in 2 courses of treatment for 5 consecutive days during postoperative Weeks 1 and 3, followed by 5-FU (100 mg/m(2)orally) daily from postoperative Week 5 until disease recurrence.
  • RESULTS: After ineligible patients were excluded, 158 patients with pancreatic carcinoma (81 in the MF group and 77 in the control group), 118 patients with bile duct carcinoma (58 in the MF group and 60 in the control group), 112 patients with gallbladder carcinoma (69 in the MF group and 43 in the control group), and 48 patients with carcinoma of the ampulla of Vater (24 in the MF group and 24 in the control group) were evaluated.
  • Good compliance (> 80%) was achieved with MF treatment.
  • There were no apparent differences in 5-year survival and 5-year DFS rates between patients with pancreatic, bile duct, or ampulla of Vater carcinomas.
  • The most commonly reported adverse drug reactions were anorexia, nausea/emesis, stomatitis, and leukopenia, none of which were noted to be serious.
  • CONCLUSIONS: The results of the current study indicate that gallbladder carcinoma patients who undergo noncurative resections may derive some benefit from systemic chemotherapy.
  • However, alternative modalities must be developed for patients with carcinomas of the pancreas, bile duct, or ampulla of Vater.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bile Duct Neoplasms / drug therapy. Common Bile Duct Neoplasms / drug therapy. Gallbladder Neoplasms / drug therapy. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Disease-Free Survival. Female. Fluorouracil / administration & dosage. Humans. Infusions, Intravenous. Male. Middle Aged. Mitomycins / administration & dosage. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2002 American Cancer Society.
  • [CommentIn] Cancer Treat Rev. 2003 Apr;29(2):135-7 [12670458.001]
  • (PMID = 12365016.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Mitomycins; U3P01618RT / Fluorouracil; FuMi protocol
  •  go-up   go-down


2. Mizuta Y, Akazawa Y, Shiozawa K, Ohara H, Ohba K, Ohnita K, Isomoto H, Takeshima F, Omagari K, Tanaka K, Yasutake T, Nakagoe T, Shirono K, Kohno S: Pseudomyxoma peritonei accompanied by intraductal papillary mucinous neoplasm of the pancreas. Pancreatology; 2005;5(4-5):470-4
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pseudomyxoma peritonei accompanied by intraductal papillary mucinous neoplasm of the pancreas.
  • This case is unique due to the concurrent presence of intraductal papillary mucinous neoplasm (IPMN) of the pancreas.
  • Abdominal computed tomography revealed massive ascites, thickened peritoneum, and a cystic lesion of the pancreas.
  • Endoscopic retrograde pancreatography revealed a cystic lesion with the defect probably due to mural nodule and mucin, communicating with the pancreatic duct.
  • No primary tumour, including mucinous neoplasm of the appendix, was found.
  • The relation between PMP and IPMN of the pancreas was possible, but not conclusive.
  • The patient received intraperitoneal perfusion of saline heated to 42 degrees C containing cisplatin, etoposide, and mitomycin C, followed by 24 courses of postoperative chemotherapy with gemcitabine.
  • The patient remains in good general condition with no signs of progression of PMP for 2 years, but with a gradual and progressive enlargement of the pancreatic cystic lesion.
  • [MeSH-major] Adenocarcinoma, Mucinous / pathology. Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / pathology. Pancreatic Neoplasms / pathology. Peritoneal Neoplasms / pathology. Pseudomyxoma Peritonei / pathology
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Ascites / pathology. Chemotherapy, Cancer, Regional Perfusion. Cisplatin / administration & dosage. Deoxycytidine / analogs & derivatives. Etoposide / administration & dosage. Humans. Hyperthermia, Induced. Infusions, Parenteral. Male. Middle Aged. Mitomycin / administration & dosage. Neoplasms, Multiple Primary

  • Genetic Alliance. consumer health - Pseudomyxoma peritonei.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2005 S. Karger AG, Basel and IAP.
  • (PMID = 15983445.001).
  • [ISSN] 1424-3903
  • [Journal-full-title] Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]
  • [ISO-abbreviation] Pancreatology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 50SG953SK6 / Mitomycin; 6PLQ3CP4P3 / Etoposide; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin
  • [Number-of-references] 19
  •  go-up   go-down


3. Hashimoto M, Umekita N, Noda K: Non-Hodgkin lymphoma as a cause of obstructive jaundice with simultaneous extrahepatic portal vein obstruction: a case report. World J Gastroenterol; 2008 Jul 7;14(25):4093-5
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography (CT) revealed a 10 cm mass in the retroperitoneal space behind the head of the pancreas causing obstruction of the distal bile duct and the PV.
  • The resected specimen showed endoluminal invasion of both the bile duct and the PV.
  • The pathologic diagnosis was diffuse large B-cell type non-Hodgkin lymphoma and the patient was transferred to the Department of Hematology and Oncology for chemotherapy.
  • He received four cycles of combined chemotherapy including cyclophosphamide, doxorubicin, vincristine and prednisone plus rituximab, and three cycles of intrathecal chemoprophylaxis including methotorexate, cytosine arbinoside and prednisone.
  • The patient is alive with no evidence of the disease for 7 mo after operation and will receive additional courses of chemotherapy.
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols. Bile Ducts / pathology. Chemotherapy, Adjuvant. Humans. Jugular Veins / transplantation. Male. Middle Aged. Neoplasm Invasiveness. Pancreaticoduodenectomy. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Hodgkin lymphoma.
  • Genetic Alliance. consumer health - Non-Hodgkin Lymphoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Gastroenterol. 2000 May;95(5):1188-94 [10811326.001]
  • [Cites] Diagn Cytopathol. 2001 Jul;25(1):43-9 [11466812.001]
  • [Cites] N Engl J Med. 2002 Jan 24;346(4):235-42 [11807147.001]
  • [Cites] Surg Today. 2003;33(1):72-4 [12560914.001]
  • [Cites] Br J Surg. 2003 Jul;90(7):845-9 [12854111.001]
  • [Cites] Gastrointest Endosc. 2003 Nov;58(5):690-5 [14595302.001]
  • [Cites] Dig Dis Sci. 2007 Sep;52(9):2323-32 [17406815.001]
  • [Cites] N Engl J Med. 1993 Apr 8;328(14):1002-6 [7680764.001]
  • [Cites] Cancer. 1993 May 1;71(9):2813-6 [7682150.001]
  • [Cites] J Hepatol. 1998 Sep;29(3):485-8 [9764999.001]
  • [Cites] Gastrointest Endosc. 2005 Apr;61(4):610-1 [15812422.001]
  • [Cites] J Gastrointest Surg. 2007 Jul;11(7):813-9 [17440790.001]
  • [Cites] AJR Am J Roentgenol. 1992 Sep;159(3):503-7 [1323924.001]
  • (PMID = 18609698.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] China
  • [Other-IDs] NLM/ PMC2725353
  •  go-up   go-down


Advertisement
4. Nguyen VX, Decker GA, Das A, Harrison ME, Silva AC, Ocal IT, Collins JM, Nguyen CC: The natural history of a branch duct intraductal papillary mucinous neoplasm in a patient with Lady Windermere syndrome: a case report. JOP; 2010;11(3):249-54

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The natural history of a branch duct intraductal papillary mucinous neoplasm in a patient with Lady Windermere syndrome: a case report.
  • CONTEXT: "Low-risk" branch duct intraductal papillary mucinous neoplasm (IPMN) is defined as pancreatic epithelial cellular proliferation of small branch ducts that lack malignant characteristics.
  • At present, our understanding of the natural history of "low-risk" branch duct IPMN is still evolving.
  • Lady Windermere syndrome is a disorder seen in non-smoking women with no pre-existing pulmonary disease affecting the lingula and/or right middle lobe with Mycobacterium avium-intracellulare complex.
  • We present a case with pancreatic adenocarcinoma after a six-year surveillance of "low-risk" branch duct IPMN in an asymptomatic elderly white woman with Lady Windermere syndrome.
  • CASE REPORT: A 79-year-old woman was referred to our institution because of pancreatic cystic abnormalities and elevated carbohydrate antigen 19-9 (CA 19-9).
  • Multiple abdominal imaging studies, endoscopic retrograde cholangiopancreatography, computer tomography, and magnetic resonance cholangiopancreatography (MRCP) were performed in the ensuing 6 years, all consistent with "low-risk" branch duct IPMN.
  • No progression was seen until year 6 when MRCP showed a 2 cm pancreatic cancer.
  • Because of multiple comorbidities, the patient chose chemotherapy over a pancreaticoduodenectomy.
  • She developed respiratory failure and died after one cycle of gemcitabine.
  • CONCLUSIONS: "Low-risk" branch duct IPMN may be a heterogeneous disease in which some cases can transform into malignant pancreatic neoplasms despite the absence of the so-called "high risk" features on imaging studies.
  • In addition, when there is coexistence of Lady Windermere syndrome and pancreatic cancer, prompt diagnosis and treatment of Lady Windermere syndrome should be considered prior to chemoradiotherapy or surgery.
  • [MeSH-major] Adenocarcinoma, Papillary / complications. Adenocarcinoma, Papillary / pathology. Carcinoma, Pancreatic Ductal / complications. Carcinoma, Pancreatic Ductal / pathology. Mycobacterium avium Complex. Mycobacterium avium-intracellulare Infection / complications

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20442521.001).
  • [ISSN] 1590-8577
  • [Journal-full-title] JOP : Journal of the pancreas
  • [ISO-abbreviation] JOP
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Italy
  •  go-up   go-down


5. Nio Y, Itakura M, Koike M, Omori H, Hashimoto K, Yano S, Higami T: A self-expandable metallic stent in combination with cholangioscopic microwave coagulation therapy and chemotherapy with oral TS-1 against obstructive jaundice due to recurrent gastric cancer: a case report of successful treatment. Anticancer Res; 2003 Mar-Apr;23(2C):1795-801
MedlinePlus Health Information. consumer health - Stomach Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A self-expandable metallic stent in combination with cholangioscopic microwave coagulation therapy and chemotherapy with oral TS-1 against obstructive jaundice due to recurrent gastric cancer: a case report of successful treatment.
  • A 45-year-old female patient had a recurrent gastric cancer at the pancreas head and it caused obstructive jaundice.
  • She was treated with percutaneous transhepatic cholangio-drainage, followed by radiotherapy and chemotherapy with cisplatin, epirubicin and 5-FU, which resulted in a prominent response and a self-expandable metallic stent was placed into the bile duct.
  • After 11 months, however, the tumor recurred and the bile duct was obstructed again by an invading tumor.
  • She was retreated with percutaneous transhepatic cholangio-drainage for jaundice, followed by chemotherapy with oral TS-1.
  • Her recurrent tumor dramatically responded again, and cholangioscopic microwave coagulation therapy was applied for the first time through a cholangio-drainage route and an additional metallic stent was inserted into the bile duct.
  • After these therapies she has been disease--free for more than 2 years.
  • In conclusion, the placement of a self-expandable metallic stent in combination with cholangioscopic microwave coagulation therapy and TS-1 was very effective in managing the obstructive jaundice due to the local recurrence of gastric cancer.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Cholestasis, Extrahepatic / therapy. Microwaves / therapeutic use. Neoplasm Recurrence, Local / complications. Oxonic Acid / therapeutic use. Pyridines / therapeutic use. Stents. Stomach Neoplasms / complications. Tegafur / therapeutic use
  • [MeSH-minor] Administration, Oral. Bile Ducts / surgery. Cautery / methods. Combined Modality Therapy. Drainage. Drug Combinations. Female. Humans. Middle Aged

  • Genetic Alliance. consumer health - Oral cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12820461.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0 / Pyridines; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


6. Yoneto T, Yoshikawa K, Fujii Y: [A patient with recurrent gallbladder cancer responding to chemotherapy with CDDP/CPT-11 and gemcitabine]. Gan To Kagaku Ryoho; 2005 Jan;32(1):99-102
Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A patient with recurrent gallbladder cancer responding to chemotherapy with CDDP/CPT-11 and gemcitabine].
  • A 79-year-old female patient was referred to our hospital for treatment of a recurrent gallbladder cancer.
  • Before admission, she had undergone expanded cholecystectomy and had been treated successfully with 5-FU for 3 years to suppress the tumor growth in intraperitoneal lymph nodes.
  • The recurrence of the tumor in lymph nodes near the pancreas head was demonstrated by computer tomography.
  • We tried a course of a combination chemotherapy consisting of CPT-11 and CDDP (40 mg CPT-11/body/day on day 1 and 10 mg CDDP/body/day on day 2-5) to reduce the size of the nodes.
  • Then, we repeated a total of 8 courses of the therapy at 4-week intervals.
  • So, we substituted gemcitabine (1 g/body/day) for the combination chemotherapy with expandable metallic stent implantation to drain the bile.
  • As a result, metastatic lymph nodes were reduced in size and the dilatation of the interhepatic bile duct disappeared.
  • Thereafter, the patient was given an additional 20 courses of gemcitabine therapy at 2-week intervals as an outpatient.
  • However, the patient died of liver metastasis 8 years after operation and 6 years after she started chemotherapy for the recurrence.
  • She maintained a good quality of life during that time.
  • The present case suggests that combination of chemotherapy protocols is effective for clinical management of gallbladder cancer recurrence, which is generally considered to be difficult to manage with chemotherapy.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Camptothecin / analogs & derivatives. Deoxycytidine / analogs & derivatives. Gallbladder Neoplasms / drug therapy. Lymph Nodes / pathology. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Aged. Cisplatin / administration & dosage. Drug Administration Schedule. Female. Humans. Lymphatic Metastasis. Survivors

  • MedlinePlus Health Information. consumer health - Gallbladder Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15675592.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0W860991D6 / Deoxycytidine; 7673326042 / irinotecan; B76N6SBZ8R / gemcitabine; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


7. Katsumata K, Tomioka H, Sumi T, Yamasaki T, Takagi M, Kato F, Suzuki Y, Aoki T, Koyanagi Y: Liver metastasis of pancreatic cancer managed by intra-arterial infusion chemotherapy combined with degradable starch microspheres. Int J Clin Oncol; 2003 Apr;8(2):110-2
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Liver metastasis of pancreatic cancer managed by intra-arterial infusion chemotherapy combined with degradable starch microspheres.
  • A patient with liver metastasis of pancreatic cancer received chemotherapy using mitomycin C and degradable starch microspheres.
  • The patient was a 52-year-old woman who had undergone surgery for cancer of the head of the pancreas in October 1996.
  • She had stage III disease and was followed up as an outpatient on oral therapy with a combined uracil and tegafur preparation.
  • In October 2000, abdominal computed tomography (CT) scans detected multiple liver metastases.
  • Three courses of intra-arterial infusion of mitomycin C and microspheres (1000 mg) resulted in regression of her tumor and a decrease of tumor marker levels.
  • After three more courses of this therapy, the patient developed bile duct necrosis and died of disseminated intravascular coagulation.
  • As her metastases were controlled for about 7 months, hepatic arterial infusion of mitomycin C and degradable starch microspheres appears to be useful for treating liver metastasis of pancreatic cancer, but careful attention should be paid to the risk of severe complications such as bile duct necrosis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / adverse effects. Bile Duct Diseases / chemically induced. Carcinoma, Hepatocellular / drug therapy. Carcinoma, Hepatocellular / secondary. Doxorubicin / analogs & derivatives. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Pancreatic Neoplasms / pathology. Starch / adverse effects
  • [MeSH-minor] Chemoembolization, Therapeutic / adverse effects. Chemoembolization, Therapeutic / methods. Chemotherapy, Adjuvant. Combined Modality Therapy. Fatal Outcome. Female. Humans. Infusions, Intra-Arterial. Middle Aged. Mitomycin / administration & dosage. Mitomycin / adverse effects. Necrosis. Neoplasm Staging. Pancreaticoduodenectomy / methods. Risk Assessment. Tomography, X-Ray Computed


8. Madanur MA, Battula N, Azam MO, Heaton N, Rela M: Chylous ascites after pancreatico-duodenectomy cholangiocarcinoma xenografts in nude mice. Hepatobiliary Pancreat Dis Int; 2007 Aug;6(4):416-9
MedlinePlus Health Information. consumer health - Liver Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The majority of cases do not develop CA, possibly due to patency of the proximal thoracic duct and good collaterals.
  • CA may be due to a consequence of occult obstruction of the proximal thoracic duct by malignant infiltration or tumor embolus.
  • RESULTS: In 138 patients who had undergone PD in our centre for pancreatic malignancy, 3 were identified with CA and managed by abdominal paracentesis.
  • Histologically, resected specimen confirmed pancreatic adenocarcinoma in all the patients.
  • Two patients developed loco-regional recurrences at a median follow up of 8 months (range 6-10 months).
  • CONCLUSIONS: CA as an uncommon postoperative complication requires frequent paracentesis, prolonged hospital stay, and delayed adjuvant chemotherapy.
  • [MeSH-major] Chylous Ascites / diagnosis. Chylous Ascites / metabolism. Duodenum / surgery. General Surgery / methods. Liver Neoplasms / diagnosis. Liver Neoplasms / pathology. Pancreas / surgery
  • [MeSH-minor] Aged. Female. Humans. Lymph Node Excision. Male. Middle Aged. Neoplasm Transplantation. Peritoneum / metabolism. Postoperative Complications. Retrospective Studies

  • Genetic Alliance. consumer health - Chylous Ascites.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17690041.001).
  • [ISSN] 1499-3872
  • [Journal-full-title] Hepatobiliary & pancreatic diseases international : HBPD INT
  • [ISO-abbreviation] HBPD INT
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  •  go-up   go-down


9. Kopchak VM, Todurov IM, Khomiak IV, Gomoliako IV, Khanenko VV, Cheverdiuk DA: [An acute necrotic pancreatitis as a complication of cystic pancreatic tumor]. Klin Khir; 2005 Aug;(8):22-5
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [An acute necrotic pancreatitis as a complication of cystic pancreatic tumor].
  • The peculiarities of the cystic pancreatic tumor morphogenesis were studied up.
  • Possibility and probability of the anastomosis existence between mucinous cystic tumor and pancreatic duct with its secondary mucinous dilatation were confirmed, causing the complications occurrence, an acute pancreatitis in particular.
  • Selecting the surgical tactic in mucinous cystic tumor it is necessary to take into account the probability of the intraductal malignization foci formation, what precludes application of extended pancreatic resection using adjuvant chemotherapy and the postoperative serological control conduction.

  • Genetic Alliance. consumer health - Pancreatitis.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16445055.001).
  • [ISSN] 0023-2130
  • [Journal-full-title] Klinichna khirurhiia
  • [ISO-abbreviation] Klin Khir
  • [Language] RUS
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Ukraine
  •  go-up   go-down


10. Hisama S, Kimura M, Nishimura T, Matsushita H, Okamura S, Saitoh S, Shimokawa Y, Arakawa A, Toyama H, Tanaka Y: [A case of pancreatic cancer treated by gemcitabine with sequential radiotherapy]. Gan To Kagaku Ryoho; 2010 Jul;37(7):1337-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of pancreatic cancer treated by gemcitabine with sequential radiotherapy].
  • A 65-year-old man suffering from acute pancreatitis underwent MRI scanning, which revealed a low signal on the T1 and T2 sequences, and hypovascularity in arterial phase in the head of the pancreas.
  • This corresponded to the area showing the absence of the lower common bile duct.
  • FDG-PET was highly suggestive of pancreatic cancer (T4N1M0, Stage IVa) with lymph node metastasis.
  • He was treated with systemic chemotherapy using gemcitabine (GEM) followed by radiotherapy.
  • The patient has been receiving systemic chemotherapy using S-1 without recurrence.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Deoxycytidine / analogs & derivatives. Pancreatic Neoplasms / drug therapy
  • [MeSH-minor] Aged. Combined Modality Therapy. Drug Combinations. Humans. Magnetic Resonance Imaging. Male. Neoplasm Staging. Oxonic Acid / therapeutic use. Remission Induction. Tegafur / therapeutic use. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20647722.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 0W860991D6 / Deoxycytidine; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


11. Pittenger GL, Taylor-Fishwick DA, Johns RH, Burcus N, Kosuri S, Vinik AI: Intramuscular injection of islet neogenesis-associated protein peptide stimulates pancreatic islet neogenesis in healthy dogs. Pancreas; 2007 Jan;34(1):103-11
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intramuscular injection of islet neogenesis-associated protein peptide stimulates pancreatic islet neogenesis in healthy dogs.
  • It has been proposed that islet neogenesis from pancreatic progenitor cells may restore insulin secretion in diabetic mammals.
  • After 30 days, pancreatic tissues were collected, and RNA and histological sections were analyzed.
  • There was a trend to increased insulin-positive cells and gene expression with treatments of 0.5 and 10 mg/kg peptide.
  • Protein gene product 9.5-positive cells were increased with treatment.
  • CONCLUSIONS: These results indicate that INGAP stimulates cells in the pancreatic duct epithelium of healthy dogs (putative islet progenitor cells) to develop along a neuroendocrine pathway and form new islets in response to INGAP peptide.
  • The INGAP might be an effective therapy for diabetes.
  • [MeSH-major] Antigens, Neoplasm / pharmacology. Biomarkers, Tumor / pharmacology. Islets of Langerhans / cytology. Islets of Langerhans / drug effects
  • [MeSH-minor] Animals. Cell Division / drug effects. Cricetinae. Diabetes Mellitus, Type 1 / drug therapy. Diabetes Mellitus, Type 2 / drug therapy. Dogs. Female. Fluorescent Antibody Technique. Injections, Intramuscular. Injections, Intravenous. Lectins, C-Type / genetics. Male. Mesocricetus. RNA, Messenger / metabolism. Recombinant Fusion Proteins / genetics. Recombinant Fusion Proteins / pharmacokinetics. Recombinant Fusion Proteins / pharmacology. Regeneration / drug effects

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17198191.001).
  • [ISSN] 1536-4828
  • [Journal-full-title] Pancreas
  • [ISO-abbreviation] Pancreas
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Lectins, C-Type; 0 / RNA, Messenger; 0 / Recombinant Fusion Proteins; 0 / pancreatitis-associated protein
  •  go-up   go-down


12. Kaiho T, Tanaka T, Tsuchiya S, Yanagisawa S, Takeuchi O, Miura M, Saigusa N, Hayasaka A, Matsuzaki O, Miyazaki M: A case of small cell carcinoma of the common bile duct. Hepatogastroenterology; 2005 Mar-Apr;52(62):363-7
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of small cell carcinoma of the common bile duct.
  • We report a case of small cell carcinoma which occurred in the common bile duct.
  • Computed tomography and ultrasonography showed a mass near the pancreas head and dilatation of the intrahepatic bile ducts.
  • Endoscopic nasobiliary drainage was undertaken, and it revealed obstruction of the common bile duct.
  • The patient was diagnosed preoperatively as having extrahepatic bile duct cancer.
  • Upon laparotomy, a tumor was found to be located in the middle common bile duct.
  • The main trunk of the portal vein and the right hepatic artery were resected concomitantly because of tumor involvement.
  • Postoperative pathological examination revealed well-differentiated papillary adenocarcinoma on the surface of the bile duct lumen, but a large part of the extraductal component was small cell carcinoma.
  • The patient then underwent two postoperative courses of systemic chemotherapy.
  • Nevertheless, she died of cancer recurrence eight months after the operation, which showed that the tumor had a highly lethal nature, with rapid and widespread dissemination.
  • Further therapeutic trials are needed to improve survival in such cases.
  • [MeSH-major] Bile Duct Neoplasms / diagnosis. Carcinoma, Small Cell / diagnosis. Common Bile Duct
  • [MeSH-minor] Aged. Chemotherapy, Adjuvant. Cholangiopancreatography, Magnetic Resonance. Fatal Outcome. Female. Humans. Neoplasm Recurrence, Local. Pancreaticoduodenectomy / methods. Tomography, X-Ray Computed. Ultrasonography

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15816436.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  •  go-up   go-down


13. Delaunoit T, Maréchal R, Hendlisz A, Eisendrath P, Legendre H, Pector JC, De Becker D, Bleiberg H: Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: an easy-to-use and well-tolerated combination. Anticancer Drugs; 2004 Aug;15(7):725-8
Hazardous Substances Data Bank. LEUCOVORIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of advanced digestive non-colon cancer with a weekly 24-h infusion of high-dose 5-fluorouracil modulated by folinic acid and cisplatin: an easy-to-use and well-tolerated combination.
  • In order to simplify treatment administration by avoiding cisplatin-related hydration, we investigated a weekly regimen of 5-FU/FA/cisplatin.
  • Patients with ADNCC were treated with 5-FU 2.0 g/m2, FA 500 mg/m2 and cisplatin 25 mg/m2 day 1, for 6 weeks with a 2-week rest, and were assessed for toxicity, tumor response and disease-free survival.
  • Primary tumor sites were mainly esophagus (n = 17), stomach (n = 12) and pancreas (n = 9).
  • Time to progression was 6.5 months.
  • Toxicity is manageable and allows chemotherapy on an outpatient basis without hydration program as required when cisplatin is used at the dose of 50 mg/m2.
  • [MeSH-major] Adenocarcinoma / drug therapy. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Digestive System Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Bile Duct Neoplasms / drug therapy. Bile Duct Neoplasms / pathology. Cisplatin / administration & dosage. Cisplatin / adverse effects. Disease Progression. Drug Administration Schedule. Esophageal Neoplasms / drug therapy. Esophageal Neoplasms / pathology. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Humans. Infusions, Intravenous. Leucovorin / administration & dosage. Leucovorin / adverse effects. Male. Middle Aged. Neoplasm Invasiveness. Pancreatic Neoplasms / drug therapy. Pancreatic Neoplasms / pathology. Stomach Neoplasms / drug therapy. Stomach Neoplasms / pathology

  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. FLUOROURACIL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15269605.001).
  • [ISSN] 0959-4973
  • [Journal-full-title] Anti-cancer drugs
  • [ISO-abbreviation] Anticancer Drugs
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] Q20Q21Q62J / Cisplatin; Q573I9DVLP / Leucovorin; U3P01618RT / Fluorouracil
  •  go-up   go-down


14. Kitami CE, Shimizu T, Sato O, Kurosaki I, Mori S, Yanagisawa Y, Ajioka Y, Hatakeyama K: Malignant islet cell tumor projecting into the main pancreatic duct. J Hepatobiliary Pancreat Surg; 2000;7(5):529-33
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Malignant islet cell tumor projecting into the main pancreatic duct.
  • We report herein a rare case of islet cell tumor showing a unique growth pattern in a patient who developed repeated acute pancreatitis as the tumor's initial symptom.
  • Preoperative imaging examinations showed dilatation of the main pancreatic duct (MPD) and cysts around the pancreatic tail.
  • A distal pancreatectomy with splenectomy was performed because the pancreatitis was localized in the distal pancreas and was not controlled by various drug therapies.
  • Grossly, the tumor consisted of two component parts: a markedly infiltrative part in the pancreatic parenchyma, and a papillary elevated part in the MPD.
  • The MPD was obstructed by the tumor spreading widely along the distal MPD.
  • Microscopically, the tumor was composed entirely of islet cell tumors (nonfunctioning), with several foci of venous and lymphatic involvement.
  • Based on its growth behavior, we assumed that the tumor may have arisen from the MPD or from islet cells closely adjacent to the MPD.
  • We discuss the growth pattern of the tumor and the cause of the pancreatitis.
  • [MeSH-major] Carcinoma, Islet Cell / pathology. Pancreatic Ducts / pathology. Pancreatic Neoplasms / pathology
  • [MeSH-minor] Acute Disease. Humans. Male. Middle Aged. Neoplasm Invasiveness. Pancreatectomy. Pancreatitis / etiology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11180883.001).
  • [ISSN] 0944-1166
  • [Journal-full-title] Journal of hepato-biliary-pancreatic surgery
  • [ISO-abbreviation] J Hepatobiliary Pancreat Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Japan
  • [Number-of-references] 22
  •  go-up   go-down


15. Shimada K, Sano T, Sakamoto Y, Kosuge T: Safe management of the pancreatic remnant with prolamine duct occlusion after extended pancreaticoduodenectomy. Hepatogastroenterology; 2005 Nov-Dec;52(66):1874-7
Hazardous Substances Data Bank. PHENYLPROPANOLAMINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Safe management of the pancreatic remnant with prolamine duct occlusion after extended pancreaticoduodenectomy.
  • BACKGROUND/AIMS: Occlusion of the pancreatic duct system has been used to prevent pancreatic leakage by abolishing pancreatic exocrine secretion in pancreatic surgery.
  • However, ductal occlusion has not proved satisfactory for preventing pancreatic fistulas in pancreaticoduodenectomy (PD).
  • METHODOLOGY: Pancreatic duct occlusion with a watertight drainage system around the pancreatic stump was performed following extended PD in 17 patients with (n=12) or without (n=5) a dilated pancreatic duct.
  • RESULTS: Transient pancreatitis during the early postoperative period occurred in all patients with a nondilated pancreatic duct.
  • No patient developed pancreatic fistula or any other serious complication in both groups.
  • CONCLUSIONS: Pancreatic duct occlusion may minimize the risk of pancreatic leakage in patients with a nondilated pancreatic duct and a normal pancreas as well as in those with a dilated, obstructed pancreatic duct without compromising the postoperative quality of life.
  • This is a safe and reliable technique for managing the pancreatic remnant in patients undergoing extended PD for advanced pancreaticobiliary malignancy.
  • [MeSH-major] Neoplasm, Residual / drug therapy. Pancreatic Ducts / drug effects. Pancreatic Fistula / prevention & control. Pancreaticoduodenectomy / adverse effects. Phenylpropanolamine / therapeutic use
  • [MeSH-minor] Adenocarcinoma / pathology. Adenocarcinoma / surgery. Adult. Aged. Anastomosis, Surgical / adverse effects. Anastomosis, Surgical / methods. Combined Modality Therapy. Female. Follow-Up Studies. Humans. Injections, Intralesional. Male. Middle Aged. Neoplasm Staging. Pancreatic Neoplasms / pathology. Pancreatic Neoplasms / surgery. Postoperative Care / methods. Probability. Retrospective Studies. Risk Assessment. Safety Management. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16334797.001).
  • [ISSN] 0172-6390
  • [Journal-full-title] Hepato-gastroenterology
  • [ISO-abbreviation] Hepatogastroenterology
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Greece
  • [Chemical-registry-number] 33RU150WUN / Phenylpropanolamine
  •  go-up   go-down


16. Erkan M, Kleeff J, Esposito I, Giese T, Ketterer K, Büchler MW, Giese NA, Friess H: Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis. Oncogene; 2005 Jun 23;24(27):4421-32
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Loss of BNIP3 expression is a late event in pancreatic cancer contributing to chemoresistance and worsened prognosis.
  • Altered expression of apoptosis-regulating genes plays an important role in the aggressive growth behavior and chemoresistance of pancreatic ductal adenocarcinoma.
  • In the present study, the hypoxia-inducible proapoptotic gene, BNIP3, was analysed in terms of expression, effect on patient survival, and chemo-responsiveness in pancreatic cancer cell lines. cDNA microarray, real-time light cycler quantitative polymerase chain reaction, laser-capture microdissection, and immunohistochemistry analyses were used to evaluate BNIP3 expression in normal and diseased pancreatic specimens.
  • The effect of chemotherapeutic agents on pancreatic cancer cells was assessed utilizing 3-(4,5-methylthiazol-2-yl)-2,5-diphenyl-tetrazolium-bromide assays.
  • BNIP3 mRNA levels were 3.0- and 6.3-fold lower in chronic pancreatitis and pancreatic cancer compared to the normal pancreas, respectively.
  • Microdissection analysis confirmed the reduction of BNIP3 expression in pancreatic cancer cells compared to normal duct cells.
  • By immunohistochemistry, BNIP3 was predominantly expressed in the acinar cells of the normal and diseased pancreas.
  • Hypoxia induced BNIP3 expression in four out of eight pancreatic cancer cell lines, while it was absent under normoxic and hypoxic conditions in the remaining four.
  • In conclusion, loss of BNIP3 expression occurs late in pancreatic cancer, contributes to resistance to chemotherapy, and correlates with a worsened prognosis.
  • [MeSH-major] Deoxycytidine / analogs & derivatives. Drug Resistance, Neoplasm. Gene Expression Regulation, Neoplastic. Membrane Proteins / deficiency. Membrane Proteins / genetics. Pancreatic Neoplasms / genetics. Pancreatic Neoplasms / pathology. Proto-Oncogene Proteins / deficiency. Proto-Oncogene Proteins / genetics
  • [MeSH-minor] Cell Line, Tumor. Fluorouracil / pharmacology. Humans. Neoplasm Staging. Prognosis. RNA, Messenger / genetics. RNA, Messenger / metabolism. RNA, Small Interfering / genetics. RNA, Small Interfering / metabolism. Survival Rate

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15856026.001).
  • [ISSN] 0950-9232
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / BNIP3 protein, human; 0 / Membrane Proteins; 0 / Proto-Oncogene Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


17. Patel VG, Eltayeb OM, Henderson VJ, Lyons R, Martin D, Hamami A, Fortson JK, Weaver WL: Primary duodenal low-grade mucosa-associated lymphoid tissue lymphoma presenting with outlet obstruction. Am Surg; 2004 Jul;70(7):613-6
MedlinePlus Health Information. consumer health - Intestinal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary duodenal low-grade mucosa-associated lymphoid tissue lymphoma presenting with outlet obstruction.
  • Low-grade lymphoma arising in mucosa-associated lymphoid tissue (MALT) of the duodenum represents a very rare neoplasm.
  • Abdominal CT scan revealed a mass in either the duodenum or head of the pancreas.
  • An endoscopic retrograde cholangiopancreatography (ERCP) was performed, which revealed a normal pancreatic duct with a large calculus in the common bile duct, which was extracted after sphincterotomy.
  • The patient developed severe nausea, vomiting, and fullness after meals.
  • Pathological examination of the resected specimen revealed a low-grade B-cell lymphoma (MALToma) arising in the duodenum and invading the pancreas.
  • Celiac, peripancreatic, pelvic, and cervical nodes were also involved with tumor.
  • The patient was postoperatively treated with chemotherapy for stage IV disease.
  • [MeSH-minor] Aged. Combined Modality Therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15279185.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Pingpank JF, Hoffman JP, Ross EA, Cooper HS, Meropol NJ, Freedman G, Pinover WH, LeVoyer TE, Sasson AR, Eisenberg BL: Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas. J Gastrointest Surg; 2001 Mar-Apr;5(2):121-30
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effect of preoperative chemoradiotherapy on surgical margin status of resected adenocarcinoma of the head of the pancreas.
  • We examined the effect of preoperative chemoradiotherapy on the ability to obtain pathologically negative resection margins in patients undergoing pancreaticoduodenectomy for adenocarcinoma of the head of the pancreas.
  • Between 1987 and 2000, 100 patients underwent Whipple resection with curative intent for primary adenocarcinoma of the head of the pancreas.
  • Pathologic assessment of six margins (proximal and distal superior mesenteric artery, proximal and distal superior mesenteric vein, pancreas, retroperitoneum, common bile duct, and hepatic artery) was undertaken by either frozen section (pancreas and common duct) or permanent section.
  • A margin was considered positive if tumor was present less than 1 mm from the inked specimen.
  • Of the 100 patients treated, 47 (47%) underwent postoperative radiation and chemotherapy (group I) and 53 (53%) received preoperative chemoradiotherapy (group II) with either 5-fluorouracil (32 patients) or gemcitabine (21 patients).
  • Patient demographics and operative parameters were similar in the two groups, with the exception of preoperative tumor size (CT scan), which was greater in group II (P < 0.001), and number of previous operations, which was greater in group II (P < 0.0001).
  • Statistical analysis of the number of negative surgical margins clear of tumor was performed using Fisher's exact test.
  • All patients (100%) had six margins assessed for microscopic involvement with tumor.
  • In the preoperative therapy group, 5 (7.5%) of 53 patients had more than one positive margin, whereas 21 (44.7%) of 47 patients without preoperative therapy had more than one margin with disease extension (P < 0.001).
  • Additionally, only 11 (25.6%) of the 47 patients without preoperative therapy had six negative margins vs. 27 (50.9%) of 53 in the group receiving preoperative therapy (P = 0.013).
  • However, this has not yet resulted in a significant increase in disease-free or overall survival for patients receiving preoperative therapy (P = 0.07).
  • [MeSH-major] Adenocarcinoma / drug therapy. Adenocarcinoma / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antimetabolites, Antineoplastic / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Female. Fluorouracil / therapeutic use. Humans. Male. Middle Aged. Neoplasm Recurrence, Local. Pancreaticoduodenectomy. Prognosis. Radiotherapy, Adjuvant. Retrospective Studies. Survival Analysis

  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Surg. 1987 Sep;206(3):366-73 [2820322.001]
  • [Cites] Am Surg. 2000 Apr;66(4):378-85; discussion 386 [10776876.001]
  • [Cites] Ann Surg. 1995 Jun;221(6):721-31; discussion 731-3 [7794076.001]
  • [Cites] Ann Surg. 1993 Feb;217(2):144-8 [8094952.001]
  • [Cites] Ann Surg. 1979 Feb;189(2):205-8 [426553.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1991 Oct;21(5):1137-43 [1938511.001]
  • [Cites] J Clin Oncol. 1997 Mar;15(3):928-37 [9060530.001]
  • [Cites] Ann Surg. 1997 Sep;226(3):248-57; discussion 257-60 [9339931.001]
  • [Cites] CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33 [10735013.001]
  • [Cites] J Surg Oncol. 2000 Apr;73(4):212-8 [10797334.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1988 Jan;14(1):79-84 [3121546.001]
  • [Cites] Cancer. 1987 Jun 15;59(12):2006-10 [3567862.001]
  • [Cites] Ann Surg. 1986 Jul;204(1):65-71 [3015059.001]
  • [Cites] Ann Surg. 1996 Mar;223(3):273-9 [8604907.001]
  • [Cites] Cancer. 1980 Nov 1;46(9):1945-9 [7427900.001]
  • [Cites] Cancer. 1976 Mar;37(3):1519-24 [1260670.001]
  • [Cites] J Clin Oncol. 1995 Jan;13(1):227-32 [7799024.001]
  • [Cites] Semin Oncol. 1992 Aug;19(4 Suppl 11):96-101 [1509287.001]
  • [Cites] Ann Surg Oncol. 1999 Jan-Feb;6(1):117-22 [10030424.001]
  • [Cites] Arch Surg. 1985 Aug;120(8):899-903 [4015380.001]
  • [Cites] World J Surg. 1997 Feb;21(2):195-200 [8995078.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Aug 30;30(1):161-7 [8083109.001]
  • (PMID = 11331473.001).
  • [ISSN] 1091-255X
  • [Journal-full-title] Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract
  • [ISO-abbreviation] J. Gastrointest. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0W860991D6 / Deoxycytidine; B76N6SBZ8R / gemcitabine; U3P01618RT / Fluorouracil
  •  go-up   go-down


19. Freelove R, Walling AD: Pancreatic cancer: diagnosis and management. Am Fam Physician; 2006 Feb 1;73(3):485-92
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pancreatic cancer: diagnosis and management.
  • Although only 32,000 new cases of adenocarcinoma of the pancreas occur in the United States each year, it is the fourth leading cause of cancer deaths in this country.
  • The link between risk of pancreatic cancer and other factors (e.g., diabetes, obesity) is less clear.
  • Most patients present with obstructive jaundice caused by compression of the bile duct in the head of the pancreas.
  • Epigastric or back pain, vague abdominal symptoms, and weight loss also are characteristic of pancreatic cancer.
  • More than one half of cases have distant metastasis at diagnosis.
  • Computed tomography is the most useful diagnostic and staging tool.
  • The majority of tumors are not surgically resectable because of metastasis and invasion of the major vessels posterior to the pancreas.
  • Resectable tumors are treated with the Whipple procedure or the pylorus-preserving Whipple procedure.
  • Adjuvant fluorouracil-based chemotherapy may prolong survival.
  • For nonresectable tumors, chemotherapy with gemcitabine prolongs survival.
  • Radiation combined with chemotherapy has slowed progression in locally advanced cancers.
  • [MeSH-major] Pancreatic Neoplasms / diagnosis. Pancreatic Neoplasms / therapy
  • [MeSH-minor] Biomarkers, Tumor / blood. Chemotherapy, Adjuvant. Diagnostic Imaging. Humans. Neoplasm Staging. Palliative Care. Physical Examination. Radiotherapy, Adjuvant

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16477897.001).
  • [ISSN] 0002-838X
  • [Journal-full-title] American family physician
  • [ISO-abbreviation] Am Fam Physician
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor
  • [Number-of-references] 51
  •  go-up   go-down


20. Haji AG, Sharma S, Majeed KA, Vijaykumar DK, Pavithran K, Dinesh M: Primary pancreatic lymphoma: Report of three cases with review of literature. Indian J Med Paediatr Oncol; 2009 Jan;30(1):20-3

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary pancreatic lymphoma: Report of three cases with review of literature.
  • BACKGROUND: Primary pancreatic lymphoma (PPL) is an extremely rare neoplasm, which may be confused with pancreatic adenocarcinoma.
  • Two patients had diagnosis confirmed histologically by CT-guided core biopsy or Fine needle aspiration procedure.
  • We were able to avoid unnecessary laparotomy in 2 patients using preoperative guided Fine needle aspiration Cytology, although the third patient did undergo a Whipple's procedure as the diagnosis of PPL was not considered during the initial workup.
  • CONCLUSIONS: There is no significant difference noted with regard to patient's age or duration of symptoms between patients with either pancreatic adenocarcinoma or PPL.
  • The differential diagnosis of PPL includes pancreatic adenocarcinoma and secondary involvement of pancreas from extra-nodal lymphoma.
  • Combination of two things is suggestive of Pancreatic lymphoma:.
  • (1) Bulky localized tumor in pancreatic head (2) Absence of significant dilatation of main pancreatic duct strengthens a diagnosis of pancreatic lymphoma over adenocarcinoma.
  • Majority of patients can be managed with chemotherapy with much better prognosis compared to patients with pancreatic adenocarcinoma.
  • Larger series of patients are needed to evaluate whether chemotherapy, eventually followed by involved-field radiation therapy, is the treatment of choice for PPL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am Surg. 1993 Aug;59(8):513-8 [8338282.001]
  • [Cites] Ann Oncol. 1993 Dec;4(10):831-7 [8117602.001]
  • [Cites] Ann Oncol. 1997 Aug;8(8):727-37 [9332679.001]
  • [Cites] J Clin Pathol. 1998 Jan;51(1):80-2 [9577380.001]
  • [Cites] Acta Cytol. 1998 May-Jun;42(3):834-6 [9622727.001]
  • [Cites] AJR Am J Roentgenol. 2000 Mar;174(3):671-5 [10701607.001]
  • [Cites] Surg Endosc. 2002 Jul;16(7):1107-8 [11984658.001]
  • [Cites] Oncology. 2001;60(4):322-9 [11408800.001]
  • [Cites] Surgery. 2001 Mar;129(3):380-3 [11231470.001]
  • [Cites] Rinsho Ketsueki. 2002 Apr;43(4):292-7 [12043211.001]
  • [Cites] Br J Surg. 1961 Jul;49:80-9 [13884035.001]
  • [Cites] Cancer. 2004 Oct 25;102(5):315-21 [15386314.001]
  • [Cites] Pancreas. 1992;7(1):118-20 [1557340.001]
  • [Cites] Arch Surg. 1989 Nov;124(11):1287-9 [2818182.001]
  • [Cites] J Surg Oncol. 1973;5(4):335-58 [4355621.001]
  • [Cites] Pancreas. 1994 Sep;9(5):662-7 [7809023.001]
  • [Cites] J Clin Gastroenterol. 1996 Sep;23(2):109-12 [8877636.001]
  • (PMID = 20668602.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2902210
  • [Keywords] NOTNLM ; Pancreatic lymphoma / neoplasm / pancreatic adenocarcinoma
  •  go-up   go-down






Advertisement